lunedì, 7 settembre 2026

Notizie AIOM – anno XV n. 624

FDA Accepts Ibrutinib Application for GVHD

April 4, 2017 - The FDA has accepted a supplemental new drug application (sNDA) for ibrutinib as a treatment for patients with chronic graft-versus-host-disease (cGVHD) after failure of 1 or more lines of systemic therapy, according to Janssen and AbbVie, the codevelopers ...
Leggi tutto

Dabrafenib/Trametinib Combo Wins EU Approval for BRAF+ NSCLC

April 3, 2017 - The European Union (EU) approved the combination of dabrafenib and trametinib for patients with BRAF V600-positive advanced or metastatic non–small cell lung cancer (NSCLC). Novartis, maker of both drugs, reported in a statement that this is the first ...
Leggi tutto